Sana Biotechnology, Inc. (NASDAQ:SANA)
| Market Cap | $476.42M-55.1% |
| Revenue (ttm) | $0 |
| Net Income | -$149.27M+36.3% |
| EPS | -$0.52+46.4% |
| Shares Out | 299.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,452,514 |
| Open | $1.70 |
| Previous Close | $1.74 |
| Day's Range | $1.56 - $1.75 |
| 52-Week Range | $1.56 - $5.49 |
| Beta | 2.30 |
| Analysts | Buy |
| Price Target | $8.67(+445.28%) |
| Earnings Date | Mar 2, 2027 |
About SANA
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
Next catalysts
- Mar 2, 2027Earnings report
$SANA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SANA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SANA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SANA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SANA Revenue by Segment
| Income (loss) from operations | $18.51M | 28.89% |
| Research, development, and laboratory | $11.82M | 18.45% |
| Facility costs | $11.55M | 18.03% |
| Support functions | $6.88M | 10.74% |
| Technical operations and manufacturing | $6.84M | 10.68% |
| Stock-based compensation | $5.33M | 8.31% |
| Other | $2.46M | 3.84% |
| Other income, net | $676.00K | 1.06% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SANA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SANA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SANA
| VTIVanguard Morningstar Total Stock Market ETF | $12.66M |
| XBIState Street SPDR S&P Biotech ETF | $9.74M |
| IWMiShares Russell 2000 ETF | $7.81M |
| VXFVanguard Extended Market ETF | $5.66M |
| IWOiShares Russell 2000 Growth ETF | $2.82M |
| VTWOVanguard Russell 2000 ETF | $2.59M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from SANA’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.63% |
| XBI | State Street SPDR S&P Biotech ETF | 0.11% |
| OPTZ | Optimize Strategy Index ETF | 0.10% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.05% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.04% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.03% |
| IBB | iShares Biotechnology ETF | 0.03% |
| PWS | Pacer WealthShield ETF | 0.02% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.02% |
| LABU | Direxion Daily S&P Biotech Bull 3X Shares | 0.02% |
| VHT | Vanguard Health Care ETF | 0.01% |
| FHLC | Fidelity MSCI Health Care Index ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
